Autopsy report · NCT00742339

Terlipressin + Albumin Versus Midodrine + Octreotide in the Treatment of Hepatorenal Syndrome

“Decision of independent monitoring committee: Risk of non-response to treatment significantly higher in midodrine group than in terlipressin group.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 years 3 months after it had already started.
• Ran for about 8 years 5 months before it stopped.
• 49 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2, Phase 3

Sponsor

University of Padova

Sponsor type

University, hospital or other

Conditions

Cirrhosis; Hepatorenal Syndrome

Interventions

Terlipressin plus albumin; Midodrine plus octreotide plus human albumin

Participants

49

Sites

1

Countries

Italy

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.